I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EHA 2025

-
Coming soon
02:00 PM
Duration 60mins Milan, Italy
2-year efficacy and safety in patients with paroxysmal nocturnal hemoglobinuria (PNH) who self-administered crovalimab▼ in the Phase III randomized COMMODORE 2 trial
Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Teresita E. Dumagay, Roberta Demichelis Gómez, Martin Höglund, Richard J. Kelly, Je-Hwan Lee, Jun-ichi Nishimura, Naoshi Obara, Antonio Risitano, Anna Gaya, Anita Appius, Hannah Staunton, Sasha Sreckovic, Sammy Chebon, Simon Buatois, Bing Han

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:00 AM
Duration 90mins Milan, Italy
Bispecific antibodies: Advances in the treatment of relapsed/refractory follicular lymphoma
Sehn L, Scholz C, Falchi L, Iacoboni G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:30 PM
Duration 60mins Milan, Italy
Mosunetuzumab▼ demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL)
Cheah CY, Barlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Shadman M, Ku M, Hess G, Gregory GP, Kim W, Wei MC, Yin S, Sit J, Tracy S, Kwan A, Penuel E, Budde EL

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:00 AM
Duration 90mins Milan, Italy
Building better outcomes for patients with diffuse large B-cell lymphoma (DLBCL): Today's treatments and tomorrow's innovations
Burke J, Gregory G, Zhao W, Dietrich S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:45 AM
Duration 15mins Allianz MiCo Milano Convention Centre
Polatuzumab vedotin▼, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized phase III POLARGO trial
Matasar M, Li Z, Vassilakopoulos T, Sancho JM, Viardot A, McMillan, A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:00 PM
Duration 15mins Allianz MiCo Milano Convention Centre
MorningSun: open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab▼ (Mosun SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL)
Burke JM, Tun AM, Villasboas J, Budde LE, Gandhi M, Graff T, Jani P, Biondo JML, Wu M, Farighi R, Mun Y, Lin T, Munoz J, Flinn I

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:30 PM
Duration 60mins Milan, Italy
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO
Gregory GP, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Ta R, Huang H, Kallemeijn MJ, Belousov A, Bottos A, Lundberg L, Abramson JS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Impact of tumor burden and prior venetoclax treatment on mosunetuzumab▼-mediated tumour control in relapsed/refractory CLL
Jin HY, Barrett K, Schroeder A, Ho H, Breton V, Penuel E, Kesavan M, Breuleux M, Sugidono M, Opat S, Tausch E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Fixed-duration subcutaneous mosunetuzumab▼ demonstrates clinically relevant efficacy in patients with relapsed/refractory follicular lymphoma with high-risk features: pivotal phase II study update
Hess G, Sehn LH, Budde EL, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Dreyling M, Guitierrez NC, Cybulski E, Sabalvaro F, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Bartlett NL

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar